High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis

被引:1
|
作者
Bejko, Dritan [1 ,6 ]
Ernst, Corinna [1 ]
Vergison, Anne [1 ]
Stranges, Saverio [2 ,3 ,4 ,5 ]
Zeegers, Maurice P. [6 ]
Mossong, Joel [1 ]
机构
[1] Hlth Directorate, Hlth Inspectorate, Luxembourg, Luxembourg
[2] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada
[3] Western Univ, Dept Family Med, London, ON, Canada
[4] Western Univ, Dept Med, London, ON, Canada
[5] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy
[6] Maastricht Univ, Sch Nutr & Translat Res Metab, Dept Epidemiol, Maastricht, Netherlands
关键词
Vaccine effectiveness; Natural immunity; COVID-19; Retrospective cohort; Hospital admission; Mortality;
D O I
10.1016/j.vaccine.2024.05.059
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Luxembourg experienced major consecutive SARS-CoV-2 infection waves due to Omicron variants during 2022 while having achieved a high vaccination coverage in 2021. We investigated the risk factors associated to severe outcomes (i.e., hospitalisation, deaths) and estimated vaccine effectiveness (VE) as well as the role of immunity conferred by prior infections against severe outcomes in adults. Methods: We linked reported SARS-CoV-2 cases among residents aged >= 20 years with vaccination data and SARS-CoV-2 related hospitalisations and deaths. Cases were followed-up until day 14 for COVID-19 related hospital admission and up to day 28 for mortality after a positive test. We analysed the association between the vaccination status and severe forms using proportional Cox regression, adjusting for previous infection, age, sex and nursing homes residency. VE was measured as 1-adjusted hazard ratio of vaccinated vs unvaccinated individuals. The population preventable fraction was computed using the adjusted hazard ratio and the proportion of cases within the vaccination category. Results: Between December 2021, and March 2023, we recorded 187143 SARS-CoV-2 cases, 1 728 (0.93%) hospitalizations and 611 (0.33%) deaths. The risk of severe outcomes increased with age, was higher among men and nursing home residents. Compared to unvaccinated adults, VE against hospitalization was 38.8% (95%CI: 28.1%-47.8%) for a complete primary cycle of vaccination, 62.1% (95%CI: 57.0%-66.7%) for one booster, and 71.6% (95%CI: 66.7%-76.2%) for two booster doses. VE against death was respectively 49.5% (95%CI: 30.8%63.3%), 69.0% (95%CI: 61.2%-75.3%) and 76.2% (95%CI: 68.4%-82.2%). Previous infection was not associated with lower risk of hospitalisation or mortality. The vaccination lowered mortality by 55.8 % (95%CI: 46.3%62.8%) and reduced hospital admissions by 49.1% (95%CI: 43.4%-54.4%). Conclusions: Complete vaccination and booster but not previous infection were protective against hospitalization and death. The vaccination program in Luxembourg led to substantial reductions in SARS-CoV-2-related mortality and hospitalizations at the population level.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] COVID-19 outbreaks in residential care homes in Hong Kong and effectiveness of vaccine against severe outcomes
    Leung, Mei Hung Joanna
    Kung, Kin Hang
    Yau, Ian Siu-kiu
    Fung, Yan Yee
    Mohammad, Kirran Nazesh
    Lau, Cheong Chi Andrew
    Au, Ka Wing Albert
    Chuang, Shuk Kwan
    INFECTIOUS MEDICINE, 2023, 2 (01): : 1 - 10
  • [32] Efficacy and effectiveness of inactivated vaccines against symptomatic COVID-19, severe COVID-19, and COVID-19 clinical outcomes in the general population: a systematic review and meta-analysis
    Law, Martin
    Ho, Sam S. H.
    Tsang, Gigi K. C.
    Ho, Clarissa M. Y.
    Kwan, Christine M.
    Yan, Vincent Ka Chun
    Yiu, Hei Hang Edmund
    Lai, Francisco Tsz Tsun
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 37
  • [33] Real-World Effectiveness of COVID-19 Vaccines against Severe Outcomes during the Period of Omicron Predominance in Thailand: A Test-Negative Nationwide Case-Control Study
    Nittayasoot, Natthaprang
    Suphanchaimat, Rapeepong
    Thammawijaya, Panithee
    Jiraphongsa, Chuleeporn
    Siraprapasiri, Taweesap
    Ploddi, Kritchavat
    Pittayawonganon, Chakkarat
    Mahasirimongkol, Surakameth
    Tharmaphornpilas, Piyanit
    VACCINES, 2022, 10 (12)
  • [34] Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak
    Ye, Wenjing
    Li, Kangguo
    Zhao, Zeyu
    Wu, Shenggen
    Qu, Huimin
    Guo, Yichao
    Abudunaibi, Buasiyamu
    Chen, Wu
    Cai, Shaojian
    Chen, Cailin
    Lin, Jiawei
    Xie, Zhonghang
    Zhan, Meirong
    Ou, Jianming
    Deng, Yanqin
    Chen, Tianmu
    Zheng, Kuicheng
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [35] Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
    Arbel, Ronen
    Peretz, Alon
    Sergienko, Ruslan
    Friger, Michael
    Beckenstein, Tanya
    Duskin-Bitan, Hadar
    Yaron, Shlomit
    Hammerman, Ariel
    Bilenko, Natalya
    Netzer, Doron
    LANCET INFECTIOUS DISEASES, 2023, 23 (08): : 914 - 921
  • [36] Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis
    Deborah Cromer
    Megan Steain
    Arnold Reynaldi
    Timothy E. Schlub
    Shanchita R. Khan
    Sarah C. Sasson
    Stephen J. Kent
    David S. Khoury
    Miles P. Davenport
    Nature Communications, 14
  • [37] Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis
    Cromer, Deborah
    Steain, Megan
    Reynaldi, Arnold
    Schlub, Timothy E.
    Khan, Shanchita R.
    Sasson, Sarah C.
    Kent, Stephen J.
    Khoury, David S.
    Davenport, Miles P.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [38] Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France
    Tchuem, Cynthia Raissa Tamandjou
    Auvigne, Vincent
    Vaux, Sophie
    Montagnat, Charline
    Paireau, Juliette
    Besnard, Stephanie Monnier
    Gabet, Amelie
    Benhajkassen, Nabil
    Le Strat, Yann
    Chatelet, Isabelle Parent Du
    Levy-Bruhl, Daniel
    VACCINE, 2023, 41 (13) : 2280 - 2288
  • [39] Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States
    Schrag, Stephanie J.
    Verani, Jennifer R.
    Dixon, Brian E.
    Page, Jessica M.
    Butterfield, Kristen A.
    Gaglani, Manjusha
    Vazquez-Benitez, Gabriela
    Zerbo, Ousseny
    Natarajan, Karthik
    Ong, Toan C.
    Lazariu, Victoria
    Rao, Suchitra
    Beaver, Ryan
    Ellington, Sascha R.
    Klein, Nicola P.
    Irving, Stephanie A.
    Grannis, Shaun J.
    Kiduko, Salome
    Barron, Michelle A.
    Midturi, John
    Dickerson, Monica
    Lewis, Ned
    Stockwell, Melissa S.
    Stenehjem, Edward
    Fadel, William F.
    Link-Gelles, Ruth
    Murthy, Kempapura
    Goddard, Kristin
    Grisel, Nancy
    Valvi, Nimish R.
    Fireman, Bruce
    Arndorfer, Julie
    Konatham, Deepika
    Ball, Sarah
    Thompson, Mark G.
    Naleway, Allison L.
    JAMA NETWORK OPEN, 2022, 5 (09) : E2233273
  • [40] Risk Factor Analysis and Nomogram for Early Progression of COVID-19 Pneumonia in Older Adult Patients in the Omicron Era
    Qi, Daoda
    Chen, Yang
    Peng, Chengyi
    Wang, Yuan
    Liang, Zihao
    Guo, Jingjing
    Gu, Yan
    CLINICAL INTERVENTIONS IN AGING, 2024, 19 : 439 - 449